VERESCA PRECISION ONCOLOGY
US | Onconostic Technologies, Inc.
EU | 3N Diagnostics Ltd.
®
PERSONALIZING TARGETED THERAPY
TODAY . . .
FOXC1 PRO-METASTIC CANCER
THE MASTER REGULATOR OF METASTASIS
ANTICIPATING BETTER OUTCOMES FOR TOMORROW.
Our Challenge
Cancer is ruthless and relentless
Technological advances during the past two decades have allowed us to understand the heterogeneous nature of (breast) cancer producing a plethora of genomic information and creating a new nomenclature of molecular subtypes.
The pharmaceutical industry has responded with therapies targeting newly discovered pathways intending to reduce recurrence risk and metastatic disease progression.
Although these new therapeutic regimens will be safe and efficacious, not everyone responds to treatment equally and patient enrichment for the targeted therapy is of critical importance.
Our tests enhance patient selection, identifying candidates who will likely achieve maximum therapeutic benefit among the broad general subclasses of cancer.
VERESCA FOXC1 IHC, a first-in-class molecular diagnostic assay, enables such precision oncology, and brings . . .
Hope for a Brighter Future.
Our Contribution
Actionable solutions to improve outcome
Forkhead box C1 IHC Test
A cost-effective solution for precision oncology
Our tests bridge the gap between complicated genomics biomarker discovery platforms and routine easy-to-use immunohistochemistry platforms available in every pathology laboratory.
Our Products
An astounding advancement in cancer diagnostics
Our tests determines the presence and degree of FOXC1 activity, a master regulator of invasion and metastasis. [89] FOXC1 is a transcriptional driver of plasticity which informs oncologists of the inherent blueprint at a molecular level of every cell in the tumor.
FOXC1 regulates the epithelial--mesenchymal transition (EMT), a process where epithelial cells separate from surrounding cells and begin migration.[1] Equally as important, FOXC1 signaling non-canonically regulates cancer stem cells (CSC) contributing to tumor proliferation, tissue invasion, relapse and chemoresistance. [2]
We empower oncologists with knowledge of tumors undergoing reconstruction with features of high metastatic propensity. Oncologists can now prescribe proper therapy abrogating disease progression based upon the extent to which remodeling has occurred at diagnostic presentation.
Molecular subtyping has brought in an era of computational algorithms and data mining of genes creating a new nomenclature. Our multi-disciplinary team translated the genomic information and analyzed the underlying pathophysiological pathways in our attempt to bring science back into medicine and actionable solutions for oncologists.
Forkhead box C1
Transcription Factor
VERESCA scientists first announced (May 2010) our landmark discovery of FOXC1, a unique gene highly overexpressed in primary tumors of basal-like breast cancer (BLBC). [3]
Our team characterized and unveiled the important role FOXC1 plays as a transcriptional driver in the metastatic cascade and disease progression. [4]
​
Along with our collaborators and colleagues, we demonstrated FOXC1 overexpression as an independent prognostic indicator with poor outcome in 20 different types of cancers. [12]
Our Technology
The master regulator of metastasis
NDSU Virtual Cell Animations Project animation: Regulated Transcription
Embedded YouTube Video. NDSUVIRTUALCELL. No modification. No endorsement.
About Us
We are a commercial stage, precision oncology company developing first-in-class molecular diagnostic solutions for routine use to enable precision oncology.
We empower oncologists with breakthrough information to prescribe a proper treatment course to minimize disease progression potentially leading to better outcomes.
​
. . .Tomorrow
Proper patient enrichment for novel therapeutic alternatives reduces morbidity and unnecessary costs of marginal treatment while improving the quality of life of people living with cancer.
Today. . .
We provide early diagnostic evidence based solutions predicting metastatic propensity and cancer recurrence, thus enabling precision oncology therapy customized for each patient.
